CytomX Therapeutics Inc
Statements
Cash Flow
CytomX Therapeutics Inc (CTMX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -18 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14 | 1.9 | -19 | 173 | -5.7 | 22 | -15 | -27 | -5.6 | -29 | -39 | -49 | -23 | -29 | -50 | 97 | -25 | -17 | -30 | -28 | -30 | -31 | -41 | -34 | -34 | -1.4 | 9.3 | -25 | -18 | -22 | -26 | -20 | -21 | -20 | -21 | -16 | -16 | -23 | -26 | -18 | -82 | |
| 0.4 | 0.5 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.4 | 0.4 | 0.4 | 0.3 | 0.1 | 0.5 | 0.0 | 0.1 | 0.8 | |
| 2.7 | 2.6 | 2.7 | 3.0 | 2.8 | 2.8 | 3.7 | 4.2 | 4.4 | 4.6 | 5.2 | 5.5 | 4.3 | 4.1 | 4.0 | 3.5 | 3.8 | 3.4 | 3.0 | 3.4 | 3.2 | 3.5 | 3.4 | 4.5 | 2.7 | 2.6 | 2.4 | 2.4 | 1.2 | 2.6 | 1.9 | 1.9 | 2.0 | 1.9 | 2.0 | 1.4 | 1.4 | 1.5 | 4.7 | 2.6 | 10 | |
| 2.7 | 12 | 2.7 | 3.0 | 2.8 | 22 | 3.7 | 4.2 | 4.4 | 4.6 | 5.2 | 7.1 | 4.3 | 4.1 | 4.0 | 3.5 | 3.8 | 3.4 | 3.0 | 4.3 | 3.2 | 3.5 | 3.4 | 5.3 | 3.5 | 3.5 | 2.4 | 2.4 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -3.1 | 12 | -14 | 195 | -9.5 | 19 | -3.0 | -17 | 13 | -1.0 | -30 | -27 | -4.1 | 1.5 | -66 | 109 | -14 | -9.8 | -19 | -14 | -12 | -10.0 | -14 | -11 | -15 | 22 | 10 | -26 | -22 | -25 | -41 | -15 | -29 | -41 | -48 | -18 | -3.3 | 0.4 | -13 | 0.0 | -16 | |
| 0.9 | 0.6 | 0.9 | 0.3 | 0.1 | 0.2 | 0.8 | 0.9 | 1.1 | 1.1 | 1.8 | 0.3 | 0.6 | 0.7 | 1.0 | 0.0 | 0.8 | 0.4 | 1.0 | 0.1 | 0.3 | 0.2 | 0.7 | 0.4 | 0.4 | 0.2 | 0.0 | 0.5 | 0.0 | 0.3 | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.3 | |
| 11 | 42 | -0.8 | 13 | 16 | -150 | -23 | 17 | -3.2 | 16 | -19 | 6.9 | 39 | 53 | 2.4 | 49 | -90 | 19 | 59 | -46 | 9.7 | -0.2 | -0.7 | -0.4 | -0.4 | 100 | -147 | 26 | -43 | 13 | 45 | 22 | 18 | 15 | 31 | -76 | 0.4 | -14 | -193 | 6.0 | -201 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 3.0 | – | – | – | |
| 0.3 | 0.0 | 0.9 | 0.7 | 1.2 | 20 | 2.6 | 0.7 | 136 | 0.7 | 0.5 | 0.7 | 0.1 | 0.4 | 2.2 | 1.5 | 0.2 | 13 | 109 | 0.7 | 0.1 | 0.7 | 0.0 | 0.5 | – | 0.7 | – | 0.3 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.3 | 0.5 | 0.9 | 0.7 | 1.2 | 21 | 2.6 | 0.7 | 136 | 0.7 | 0.5 | 0.7 | 0.1 | 0.4 | 2.2 | 1.5 | 0.2 | 13 | 109 | 0.7 | 0.1 | 0.7 | 0.0 | 0.5 | 0.5 | 0.2 | 0.3 | 0.3 | 30 | 0.2 | 0.2 | 5.1 | 0.0 | 2.2 | 0.0 | 94 | 0.3 | 17 | 234 | 0.5 | 252 | |
| -2.6 | 45 | -19 | 187 | 11 | -107 | -35 | -9.2 | 127 | -12 | -57 | -41 | 15 | 24 | -45 | 148 | -115 | 15 | 138 | -74 | -20 | -31 | -42 | -34 | -34 | 99 | -137 | 1.2 | -32 | -8.9 | 19 | 7.1 | -2.6 | -2.5 | 9.6 | 1.4 | -15 | -21 | 16 | -12 | -31 | |
| -15 | 1.3 | -20 | 173 | -5.8 | 22 | -15 | -27 | -6.6 | -30 | -41 | -49 | -24 | -30 | -51 | 97 | -25 | -18 | -31 | -28 | -30 | -31 | -42 | -35 | -34 | -1.6 | 9.3 | -26 | -18 | -22 | -26 | -20 | -21 | -20 | -21 | -16 | -15 | -23 | -26 | -18 | -82 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.